Wordt geladen...
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. The majority of complete responders with metastatic renal cell carcinoma (mRCC) and metastati...
Bewaard in:
| Gepubliceerd in: | J Immunother Cancer |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6889624/ https://ncbi.nlm.nih.gov/pubmed/31546315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-014-0026-0 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|